Global scale Evonik operates in over 100 countries with 31,000 employees and €14.1 billion in revenue, indicating broad market reach and multiple cross-border sales opportunities across industries that rely on specialty chemicals and advanced materials.

AI and biotech Recent collaborations and investments in AI pilots and biotechnology assets, including a Singapore facility pilot with Imubit and a €80 million fermentation plant expansion in Slovakia, signal opportunities to position Evonik’s process optimization, data-enabled manufacturing, and biotech capabilities to customers seeking efficiency and new bio-based solutions.

Advanced materials New Lab and collaborations around PEEK Rectangular Magnet Wire and polyamide solutions indicate demand from electronics, automotive, and sports goods sectors for high-performance materials and customized solutions that Evonik can tailor to end markets.

Strategic partnerships Strengthened distribution agreements and cross-continental partnerships, such as with First Quality Chemicals and O’Rec Group for membranes, suggest a channel-focused path to accelerate penetration in downstream markets and regional growth in Latin America, Europe, and Southeast Asia.

Capital investments Significant capital deployment in new assets and centers of excellence across Europe and Asia demonstrates Evonik’s commitment to capacity expansion and capability building, creating sales opportunities for customers seeking scalable supply of specialty chemicals, biotechnological products, and high-value materials.